BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang HK, Liu PP, Hsu JY, Lin SM, Peng CC, Wang JH, Loh CH. Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study. Eur Heart J 2020;41:1100-8. [PMID: 32006423 DOI: 10.1093/eurheartj/ehz952] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 24.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang N, Zhao Y, Bai Z, Chen H, Ning H, Zou M, Cheng G. The association of non-vitamin K antagonist oral anticoagulants vs. warfarin and the risk of fractures for patients with atrial fibrillation: a systematic review and meta-analysis. Acta Cardiol 2022;:1-13. [PMID: 36063197 DOI: 10.1080/00015385.2022.2030555] [Reference Citation Analysis]
2 Tsai SHL, Hu C, Shao S, Tischler EH, Obisesan OH, Vervoort D, Chen WC, Hu J, Kuo L. Comparative Risks of Fracture Among Direct Oral Anticoagulants and Warfarin: A Systematic Review and Network Meta-Analysis. Front Cardiovasc Med 2022;9:896952. [DOI: 10.3389/fcvm.2022.896952] [Reference Citation Analysis]
3 Xie X, Liu Y, Li J, Gu F, Zhang K, Sui Z, Zhang J, Yu T. Fracture risks in patients with atrial fibrillation treated with different oral anticoagulants: a meta-analysis and systematic review. Age Ageing 2022;51:afab264. [PMID: 35077554 DOI: 10.1093/ageing/afab264] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zhou J, Lee S, Liu X, Iltaf Satti D, Tai Loy Lee T, Hou In Chou O, Chang C, Roever L, Tak Wong W, Ka Chung Wai A, Liu T, Zhang Q, Tse G. Hip fractures risks in edoxaban versus warfarin users: A propensity score-matched population-based cohort study with competing risk analyses. Bone 2021;156:116303. [PMID: 34973496 DOI: 10.1016/j.bone.2021.116303] [Reference Citation Analysis]
5 Crea F. Hot topics in congenital heart disease and new insight into ventricular non-compaction. Eur Heart J 2021;42:4197-201. [PMID: 34724708 DOI: 10.1093/eurheartj/ehab746] [Reference Citation Analysis]
6 Crea F. Thrombosis in peripheral artery disease and thrombotic thrombocytopenia after adenoviral COVID-19 vaccination. Eur Heart J 2021;42:3995-9. [PMID: 34649281 DOI: 10.1093/eurheartj/ehab712] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Cases A, Gomez P, Broseta JJ, Perez Bernat E, Arjona Barrionuevo JD, Portolés JM, Gorriz JL. Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review. Front Med (Lausanne) 2021;8:654620. [PMID: 34604247 DOI: 10.3389/fmed.2021.654620] [Reference Citation Analysis]
8 Crea F. The ESC Guidelines on cardiac pacing and resynchronization, and the many facets of atrial fibrillation. Eur Heart J 2021;42:3411-4. [PMID: 34521100 DOI: 10.1093/eurheartj/ehab628] [Reference Citation Analysis]
9 Mongkhon P, Fanning L, Wong KHTW, Man KKC, Wong ICK, Lau WCY. Non-vitamin K oral anticoagulants and risk of fractures: a systematic review and meta-analysis. Europace 2021;23:39-48. [PMID: 33085751 DOI: 10.1093/europace/euaa242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wu X, Hu L, Liu J, Gu Q. Association of Direct Oral Anticoagulants vs. Vitamin K Antagonists With Fractures in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis. Front Cardiovasc Med 2021;8:713187. [PMID: 34368263 DOI: 10.3389/fcvm.2021.713187] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Khanra D, Mukherjee A, Deshpande S, Khan H, Kathuria S, Kella D, Padmanabhan D. A Network Meta-Analysis Comparing Osteoporotic Fracture among Different Direct Oral Anticoagulants and Vitamin K Antagonists in Patients with Atrial Fibrillation. J Bone Metab 2021;28:139-50. [PMID: 34130366 DOI: 10.11005/jbm.2021.28.2.139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Lüscher TF. Challenges in atrial fibrillation: detection, alert systems, fibrosis, and infection. Eur Heart J 2020;41:1063-6. [PMID: 33216858 DOI: 10.1093/eurheartj/ehaa153] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Huang HK, Yeh JI, Loh CH. Hip fracture risk in patients with atrial fibrillation receiving oral anticoagulants: a meta-analysis based on current observational studies. Eur Heart J 2020;41:2919-20. [PMID: 32380541 DOI: 10.1093/eurheartj/ehaa361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Huang HK, Peng CC, Lin SM, Munir KM, Chang RH, Wu BB, Liu PP, Hsu JY, Loh CH, Tu YK. Fracture Risks in Patients Treated With Different Oral Anticoagulants: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2021;10:e019618. [PMID: 33759542 DOI: 10.1161/JAHA.120.019618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kim D, Yang P, Sung J, Jang E, Yu HT, Kim T, Uhm J, Kim J, Pak H, Lee M, Lip GYH, Joung B. Risk for osteoporotic fractures in patients with atrial fibrillation using different oral anticoagulants. Int J Arrhythm 2021;22. [DOI: 10.1186/s42444-021-00032-0] [Reference Citation Analysis]
16 Chen J, Lyu L, Shen J, Zeng C, Chen C, Wei T. The association of fracture risk in atrial fibrillation patients and long-term anticoagulant therapy category: a systematic review and meta-analysis. PeerJ 2021;9:e10683. [PMID: 33552723 DOI: 10.7717/peerj.10683] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Patil T, Hobson J. Risk of new-onset osteoporosis in single-center veteran population receiving direct oral anticoagulants versus warfarin. Thromb Res 2021;200:56-63. [PMID: 33540293 DOI: 10.1016/j.thromres.2021.01.019] [Reference Citation Analysis]
18 Chou MC, Huang JY, Hung YM, Perng WT, Chang R, Wei JC. Flat foot and spinal degeneration: Evidence from nationwide population-based cohort study. J Formos Med Assoc 2021;120:1897-906. [PMID: 33423898 DOI: 10.1016/j.jfma.2020.12.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 De Caterina R, Mundi S, Fusaro M. Vitamin K antagonists and osteoporotic fractures: insights from comparisons with the NOACs. Eur Heart J 2020;41:1109-11. [PMID: 32083296 DOI: 10.1093/eurheartj/ehaa077] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
20 Fusaro M, Cianciolo G, Evenepoel P, Schurgers L, Plebani M. Vitamin K in CKD Bone Disorders. Calcif Tissue Int 2021;108:476-85. [PMID: 33409597 DOI: 10.1007/s00223-020-00792-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
21 Huang HK, Liu PP, Lin SM, Hsu JY, Peng CC, Munir KM, Wu TY, Yeh JI, Loh CH, Tu YK. Risk of developing diabetes in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants or warfarin: A nationwide cohort study. Diabetes Obes Metab 2021;23:499-507. [PMID: 33140538 DOI: 10.1111/dom.14243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
22 Sugiyama T. An update on hip fracture risk associated with anticoagulant therapy: warfarin versus direct oral anticoagulants. Expert Opin Drug Saf 2020;19:1219-20. [PMID: 32795203 DOI: 10.1080/14740338.2020.1811230] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Lüscher TF. Optimizing management of atrial fibrillation: integrated care, blood pressure control, ablation, and left atrial appendix occlusion. Eur Heart J 2020;41:2821-5. [PMID: 33216915 DOI: 10.1093/eurheartj/ehaa676] [Reference Citation Analysis]
24 Sugiyama T. Hip fracture risk in patients with atrial fibrillation receiving oral anticoagulants. Eur Heart J 2020;41:2918. [PMID: 32380552 DOI: 10.1093/eurheartj/ehaa297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 He N, Dell'Aniello S, Zhai S, Suissa S, Renoux C. Risk of fracture in patients with non-valvular atrial fibrillation initiating direct oral anticoagulants vs. vitamin K antagonists. Eur Heart J Cardiovasc Pharmacother 2021;7:389-97. [PMID: 32722764 DOI: 10.1093/ehjcvp/pvaa094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
26 Marietta M, Coluccio V, Boriani G, Luppi M. Effects of Anti-vitamin k oral anticoagulants on bone and cardiovascular health. Eur J Intern Med 2020;79:1-11. [PMID: 32553585 DOI: 10.1016/j.ejim.2020.05.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]